Seelos Therapeutics (NASDAQ:SEEL) Trading Down 5.4%

Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Rating)’s share price was down 5.4% during trading on Friday . The company traded as low as $0.92 and last traded at $0.93. Approximately 373,851 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 494,196 shares. The stock had previously closed at $0.98.

Seelos Therapeutics Trading Down 5.4 %

The stock has a fifty day moving average of $0.88 and a 200 day moving average of $0.96. The company has a market capitalization of $99.15 million, a P/E ratio of -1.17 and a beta of 2.04. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.85 and a current ratio of 1.85.

Seelos Therapeutics (NASDAQ:SEEL – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.18) EPS for the quarter. As a group, equities research analysts anticipate that Seelos Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Seelos Therapeutics

Several large investors have recently made changes to their positions in SEEL. Exchange Traded Concepts LLC grew its position in Seelos Therapeutics by 155.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 42,657 shares of the company’s stock worth $29,000 after acquiring an additional 25,935 shares in the last quarter. WealthPlan Investment Management LLC purchased a new position in shares of Seelos Therapeutics during the third quarter valued at approximately $86,000. Vanguard Group Inc. boosted its position in shares of Seelos Therapeutics by 1.8% during the third quarter. Vanguard Group Inc. now owns 5,014,340 shares of the company’s stock valued at $5,164,000 after buying an additional 86,990 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Seelos Therapeutics during the third quarter valued at approximately $93,000. Finally, SG Americas Securities LLC bought a new stake in shares of Seelos Therapeutics during the third quarter valued at approximately $56,000. 25.39% of the stock is owned by institutional investors.

Seelos Therapeutics Company Profile

(Get Rating)

Seelos Therapeutics, Inc is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm’s portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.